10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)

AstraZeneca

Status: Completed

Conditions: Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT00885612

NIS-OKR-DUM-2009/1

Details and patient eligibility

About

10-year CHD risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer patients taking aromatase inhibitors.

Enrollment: 1,114 patients

Sex: Female

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Early Breast Cancer patients
• Postmenopausal Status
• patients taking Aromatase Inhibitor as adjuvant treatment no longer than 6 months

Exclusion criteria

• Advanced Breast Cancer patients(stage iii, iv)
• Patients who are hard to be analysed by limitation of chart record according to investigators discretion
• patients who already have been registered in this study